1-(溴甲基)-4-乙基环己烷 | 81472-31-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 中文名称: 1-(溴甲基)-4-乙基环己烷
• 英文名称: trans-4-ethylcyclohexylmethyl bromide
• 英文别名: 1-(Bromomethyl)-4-ethylcyclohexane
• CAS: 81472-31-3；1516772-83-0
• 化学式: C₉H₁₇Br
• 分子量: 205.138
• InChiKey: GTTAKDFRWSHWKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(溴甲基)-4-乙基环己烷 在 magnesium 作用下， 以 乙醚 为溶剂， 生成
  参考文献：
  名称：

  Takatsu; Takeuchi; Sato, Molecular Crystals and Liquid Crystals (1969-1991), 1983, vol. 94, # 3-4, p. 255 - 266

  摘要：

  DOI：
• 作为产物：
  描述：

  (4-ethylcyclohexyl)methanol 在 氢溴酸 作用下， 生成 1-(溴甲基)-4-乙基环己烷
  参考文献：
  名称：

  Takatsu; Takeuchi; Sato, Molecular Crystals and Liquid Crystals (1969-1991), 1983, vol. 94, # 3-4, p. 255 - 266

  摘要：

  DOI：

文献信息

• [EN] 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS<br/>[FR] PURINES 2,6,7,8-SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HDM2
  申请人：MERCK SHARP & DOHME

  公开号：WO2014120748A1

  公开（公告）日：2014-08-07

  The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供如本文所述的2,6,7,8取代嘌呤或其药学上可接受的盐。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• Carboxylate derivatives comprising an ether group and liquid crystal
  申请人：Chisso Corporation

  公开号：US06149990A1

  公开（公告）日：2000-11-21

  A compound represented by the following general formula (I), a liquid crystal composition comprising the same, and a liquid crystal element using this liquid crystal composition. ##STR1## (wherein B.sub.1 and B.sub.2 represent independently a trans-1,4-cyclohexylene group or a 1,4-phenylene group wherein at least one hydrogen atom on the six-membered ring is optionally substituted by a halogen atom, Y represents a halogen-substituted alkyl group having 1 to 3 carbon atoms, a halogen-substituted alkoxy group having 1 to 3 carbon atoms, a cyano group, a fluorine atom or a chlorine atom, X represents a fluorine atom, a chlorine atom or a hydrogen atom, R.sub.1 represents an alkyl group having 1 to 10 carbon atoms or an alkoxy group having 1 to 10 carbon atoms, n and m represent independently 1 or 2 and p represents 0 or 1.) The compound of the present invention exhibits a large dielectric anisotropy, low threshold voltage, and favorable temperature-dependency of threshold voltage, as well as a favorable miscibility with a known liquid crystal compound, and therefore a liquid crystal composition comprising the compound can provide low voltage-operable liquid crystal display elements.

  由以下一般公式（I）表示的化合物，包含相同化合物的液晶组合物，以及使用该液晶组合物的液晶元件。其中B.sub.1和B.sub.2分别代表一个trans-1,4-环己亚基或一个1,4-苯亚基，其中六元环上至少一个氢原子可以选择性地被卤素原子取代，Y代表具有1至3个碳原子的卤素取代烷基基团，具有1至3个碳原子的卤素取代烷氧基团，氰基，氟原子或氯原子，X代表氟原子，氯原子或氢原子，R.sub.1代表具有1至10个碳原子的烷基基团或具有1至10个碳原子的烷氧基团，n和m分别独立地代表1或2，p代表0或1。本发明的化合物具有较大的介电各向异性，低阈值电压，以及阈值电压的良好温度依赖性，以及与已知液晶化合物的良好互溶性，因此包含该化合物的液晶组合物可以提供低电压操作的液晶显示元件。
• Pre-organized tricyclic integrase inhibitor compounds
  申请人：Chen James M.

  公开号：US20090029939A1

  公开（公告）日：2009-01-29

  Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. A 1 and A 2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl, Q is N, + NR, or CR 4 . The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.

  本发明揭示了以下结构的三环化合物、其保护中间体以及抑制HIV整合酶的方法。其中，A1和A2是形成五、六或七元环的基团。L是连接Ar环原子和N的键或连接剂。X是O、S或取代的氮。Ar是芳基或杂环芳基，Q是N、+NR或CR4。芳基碳可以独立地被取代为除氢以外的取代基。这些化合物可以包括共价连接在任何位置的前药基团。
• 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150353553A1

  公开（公告）日：2015-12-10

  The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的2,6,7,8取代嘌呤或其药学上可接受的盐。这些代表性化合物可用作HDM2蛋白的抑制剂。本发明还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME
  申请人：Kawakami Shotaro

  公开号：US20090200514A1

  公开（公告）日：2009-08-13

  A nematic liquid crystal composition of the present invention includes one or at least two compounds represented by general formula (I) as a first component; and one or at least two compounds represented by general formula (II) as a second component, wherein a dielectric anisotropy is negative. The use of this nematic liquid crystal composition can provide a highly reliable liquid crystal display element capable of maintaining a high voltage-holding ratio even in a high temperature region, and achieving quick responsiveness without reducing the cell gap.

  本发明的向列型液晶组分包括至少一种由通式（I）表示的化合物作为第一组分，以及至少一种由通式（II）表示的化合物作为第二组分，其中介电各向异性为负。使用这种向列型液晶组分可以提供高度可靠的液晶显示元件，即使在高温区域也能保持高电压保持比率，并且在不减小单元间距的情况下实现快速响应。